Is there still room for pioglitazone in contemporary type 2 diabetes management?
Crossref DOI link: https://doi.org/10.1186/s12933-026-03093-4
Published Online: 2026-03-16
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Caruso, Irene
Text and Data Mining valid from 2026-03-16
Version of Record valid from 2026-03-16
Article History
Received: 19 December 2025
Accepted: 18 January 2026
First Online: 16 March 2026
Declarations
:
: Speaker fees from Eli Lilly, Novo Nordisk, Boeringher Inghelheim.Travel support from Abbott, Guidotti SpA.